Excellence at the point of care
We are committed to helping pioneer a new era in diagnostic technology, where the results from DNA and RNA-based tests can be obtained in the moment of need, at the point of care.
Founded in 2010 with a vision to bring centralized lab quality results to the point of care, we are prioritizing the development of infectious disease test panels for women’s and sexual health providers.
NEW ERA OF TESTING
The COVID-19 pandemic accelerated the development of molecular point-of-care platforms to bring rapid respiratory testing closer to patients.
NEW ERA OF TESTING
At Talis Biomedical, we are pioneering science and technology to diagnose infectious disease rapidly, accurately, and directly at the point of care. Fueled by excellence and clinical rigor, we’re developing a robust menu of tests for women’s and sexual health.
One system, multiple applications
Access to molecular diagnostics at the point of care, enbales timely results for actionable decision making. In the future,
our Talis One portfolio of diagonositc tests will include solutions for multiple infectious disease states in a variety of settings.
© Talis Biomedical Corporation. All Rights Reserved.
Talis One is a registered trademark of Talis Biomedical Corporation.
* Testing solutions are currently in development and not available for sale.
* †The Talis Biomedical One Test System is not authorized, cleared, or approved by the FDA and is not available for sale.